Everything below concerns peptidase cleavage. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
=== mRNA === C3orf52 has two transcript variants. Transcript variant 1 is a shorter transcript (753 nucleotides) but encodes a longer isoform (TPA-induced transmembrane protein isoform 1). Transcript variant 2 (654 nucleotides) encodes a shorter isoform (TPA- induced transmembrane protein isoform 2) with a different C-terminus. Transcript variant 2 consists of six exons.
==== Early career ==== He was recruited to the AFL by Essendon from the 1990 AFL draft; however, due to a serious hip injury along with other injuries in his junior football career, he was not selected until pick number 79, Essendon's seventh pick and one of the last in the draft. Due to injury, Hird missed out on playing for most of 1991, his first season with the club. At the end of the season, a vote was held on whether to delist him. The majority (4–2) voted in favour of Hird being delisted, but coach Kevin Sheedy, sensing a promising future for the young Hird, voted to keep him. Ultimately, Hird remained with the club. He made his senior debut against St Kilda in 1992 at Waverley Park as a late replacement for former captain Terry Daniher. Hird spent most of the season in the Essendon Reserves, which, under Denis Pagan, won the premiership that season. He achieved regular selection in the Essendon senior team during the 1993 season. In that season, he was a member of what was referred to as the "Baby Bombers", a group of young players (most notably including Hird, Mark Mercuri, Gavin Wanganeen, Dustin Fletcher, Ricky Olarenshaw, David Calthorpe, Paul Hills and Joe Misiti) that played a key role in the side winning the premiership that year. In 1994, Hird won the first of three consecutive best-and-fairest awards, culminating in his 1996 season that earned him a Brownlow Medal. A series of injuries restricted Hird's appearances during the remainder of the 1990s.
Jaw pain and neuropathy Loose teeth Mucosal swelling Erythema Suppuration Soft tissue ulceration persisting for more than 8 weeks Trismus Non-healing extraction sockets Paraesthesia or numbness in the jaw Bad breath Exposed necrotic jaw bone
Sources: en.wikipedia.org
A typical APCI source usually consists of three main parts: a sample inlet, a corona discharge needle, and an ion transfer region under intermediate pressure. In the case of the heated nebulizer inlet from an LC, as shown in the figure, the eluate flows at 0.2 to 2.0 mL/min into a pneumatic nebulizer which creates a mist of fine droplets. Droplets are vaporized by impact with the heated walls at 350–500 °C and carried by the nebulizer gas and an auxiliary gas into the ion molecule reaction region between the corona electrode and the exit counter-electrode. A constant current of 2–5 microamps is maintained from the corona needle. Sample ions are produced by ion-molecule reactions (as described below), and pass through a small orifice or tube into the ion transfer region leading to the mass spectrometer. Various geometries of ion source are possible, depending on application. When used with liquid chromatography, particularly at higher flow rates, the nebulizer is often positioned orthogonal to (or at a similarly steep angle to) the inlet of the mass spectrometer, so that solvent and neutral material does not contaminate the actual inlet of the mass spectrometer.
Several international trade union organizations, including the International Trade Union Confederation, Trade Union Confederation of the Americas, and the World Federation of Trade Unions, condemned the attack. Environmental NGOs, including Greenpeace and Oil Change International, have criticised the United States' oil-motivated actions in Venezuela and reiterated calls for a just transition away from fossil fuels. The Federal Council of Switzerland decided to freeze any assets held in the country by Nicolás Maduro.
== Further reading == Slater, Anna G.; Cooper, Andrew I. (2015-05-29). "Function-led design of new porous materials". Science. 348 (6238) aaa8075. doi:10.1126/science.aaa8075. PMID 26023142. Satoh, Yusuke; Matsuno, Hirohiko; Yamamato, Takuya; Tajima, Kenji; Isono, Takuya; Satoh, Toshifumi (2017). "Synthesis of Well-Defined Three- and Four-Armed Cage-Shaped Polymers via "Topological Conversion" from Trefoil- and Quatrefoil-Shaped Polymers". Macromolecules. 50 (1): 97–106. Bibcode:2017MaMol..50...97S. doi:10.1021/acs.macromol.6b02316. Mato, Yoshinobu; Honda, Kohei; Tajima, Kenji; Yamamato, Takuya; Isono, Takuya; Satoh, Toshifumi (2019). "A versatile synthetic strategy for macromolecular cages: intramolecular consecutive cyclization of star-shaped polymers". Chemical Science. 10 (2): 440–446. doi:10.1039/C8SC04006K. PMC 6335864. PMID 30746091. Lee, Taeheon; Oh, Joongsuk; Jeong, Jonghwa; Jung, Haeji; Huh, June; Chang, Taihyun; Paik, Hyun-jong (2016-05-24). "Figure-Eight-Shaped and Cage-Shaped Cyclic Polystyrenes". Macromolecules. 49 (10): 3672–3680. Bibcode:2016MaMol..49.3672L. doi:10.1021/acs.macromol.6b00093. ISSN 0024-9297.
== Contraindications == Ethylestrenol should not be taken by pregnant women as it can masculinize female fetuses. It is contraindicated in men with prostate cancer as it may accelerate the progression of the disease.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.